Central Adiposity and Visceral Fat: Risks and Treatment

Central adiposity and visceral fat are increasingly recognised as key drivers of cardiometabolic disease, independent of overall body weight. Unlike subcutaneous fat stored beneath the skin, visceral fat accumulates around the internal organs and releases inflammatory compounds and fatty acids directly into the portal circulation, disrupting insulin signalling and lipid metabolism. This article explains what central adiposity means clinically, how it is measured in UK practice, the health risks it carries, and what dietary, lifestyle and medical interventions are available through the NHS to reduce visceral fat and lower long-term disease risk.

What is central adiposity and why does visceral fat matter?

Central adiposity is the accumulation of excess fat around the abdomen; visceral fat is particularly harmful because it releases inflammatory compounds and fatty acids directly into the portal circulation, disrupting insulin signalling and raising cardiometabolic risk independently of total body weight.

Central adiposity refers to the accumulation of excess fat around the abdomen and trunk, and it is considered more metabolically harmful than fat stored elsewhere in the body. Body fat broadly divides into two types: subcutaneous fat, which sits just beneath the skin, and visceral fat, which surrounds the internal organs within the abdominal cavity. It is visceral fat that drives the greatest health concern.

Visceral fat is metabolically active tissue. It releases fatty acids, inflammatory cytokines and hormones directly into the portal circulation, which feeds the liver. This proximity to the liver and other vital organs means visceral fat can disrupt insulin signalling, promote systemic inflammation and alter lipid metabolism in ways that subcutaneous fat does not. People with a high proportion of visceral fat may appear only moderately overweight by overall body weight measures, yet still carry a substantially elevated cardiometabolic risk.

Central adiposity is not simply a cosmetic concern. Research consistently shows that the distribution of fat, rather than total fat mass alone, is a strong predictor of conditions including type 2 diabetes, cardiovascular disease and certain cancers. This is why clinicians and public health bodies in the UK increasingly focus on where fat is stored, not just how much a person weighs. Understanding the distinction between visceral and subcutaneous fat helps explain why two individuals with the same body mass index (BMI) can have very different health profiles.

How do doctors measure central adiposity in the UK?

Waist circumference is the primary clinical measure, with NICE thresholds of 94 cm and 102 cm for men and 80 cm and 88 cm for women; lower cut-offs apply for South Asian, Chinese and Japanese adults.

Waist circumference is the most widely used clinical measure of central adiposity in UK practice, and NICE guidance supports its use alongside BMI to assess cardiometabolic risk.^[2] A simple tape measure placed midway between the lower rib and the top of the hip bone (the iliac crest) provides a reproducible reading that correlates well with visceral fat burden. NICE and NHS guidance identify thresholds above which health risk increases substantially: for men, a waist circumference above 94 cm indicates increased risk, and above 102 cm indicates high risk; for women, the corresponding thresholds are 80 cm and 88 cm.^[2] These thresholds differ by ethnicity, and lower cut-offs apply for people of South Asian, Chinese and Japanese descent, reflecting evidence that visceral fat accumulates at lower overall body weights in these groups.^[2][5] For example, NICE public health guidance on BMI and ethnicity notes that South Asian adults face increased risk at lower waist measurements than the general thresholds above.

Waist-to-hip ratio and waist-to-height ratio are additional tools used in research and some clinical settings. A waist-to-height ratio above 0.5 is broadly considered a marker of elevated risk across adult populations. These ratios can add nuance when BMI alone is misleading, for example in individuals with high muscle mass.

More precise quantification of visceral fat requires imaging. Computed tomography (CT) and magnetic resonance imaging (MRI) can directly measure visceral adipose tissue volume, and dual-energy X-ray absorptiometry (DEXA) scanning provides detailed body composition data. However, these techniques are generally reserved for research or specialist clinical assessment rather than routine primary care, given their cost and resource requirements. In everyday NHS practice, waist circumference remains the practical, accessible and evidence-supported first-line measure.

What health risks are linked to carrying excess visceral fat?

Excess visceral fat independently raises the risk of type 2 diabetes, cardiovascular disease, MASLD, obstructive sleep apnoea and certain cancers, and drives metabolic syndrome through hepatic insulin resistance, dyslipidaemia and hypertension.

Excess visceral fat is independently associated with a significantly elevated risk of type 2 diabetes, cardiovascular disease, metabolic dysfunction-associated steatotic liver disease (MASLD, formerly known as non-alcoholic fatty liver disease or NAFLD), obstructive sleep apnoea and certain cancers, including colorectal and postmenopausal breast cancer. These associations hold even after adjusting for overall BMI, underscoring that fat distribution carries prognostic information beyond total body weight.

The mechanisms are well characterised. Visceral adipose tissue secretes pro-inflammatory adipokines such as tumour necrosis factor-alpha (TNF-alpha) and interleukin-6, and releases free fatty acids into the portal vein. This drives hepatic insulin resistance, promotes dyslipidaemia (characterised by raised triglycerides and low HDL cholesterol) and contributes to endothelial dysfunction. Together, these changes form the cluster of abnormalities known as metabolic syndrome, which substantially amplifies cardiovascular risk.

Central adiposity is also linked to hypertension. Visceral fat activates the renin-angiotensin-aldosterone system and increases sympathetic nervous system activity, both of which raise blood pressure.^[7][8] In people with pre-existing type 2 diabetes, high visceral fat burden is associated with poorer glycaemic control and a greater likelihood of requiring intensified treatment.

It is important to note that risk exists on a continuum. Even modest reductions in waist circumference, achievable through lifestyle change, are associated with meaningful improvements in metabolic markers. Clinicians should communicate this clearly: the goal is not necessarily to reach an idealised body shape, but to reduce visceral fat sufficiently to lower the risk of serious long-term conditions. Early identification and intervention remain central to NHS prevention strategies.

Can diet and exercise reduce visceral fat effectively?

Yes; lifestyle intervention consistently produces proportionally greater reductions in visceral fat than subcutaneous fat, with combined aerobic and resistance exercise alongside a calorie-reduced or Mediterranean-style diet being most effective.

Diet and exercise can reduce visceral fat effectively, and evidence consistently shows that lifestyle intervention produces proportionally greater reductions in visceral fat than in subcutaneous fat. This is clinically significant because it means that even modest weight loss, typically in the range of 5 to 10 per cent of body weight, can produce disproportionate improvements in metabolic risk markers.

Dietary approaches that have demonstrated benefit for visceral fat reduction include:

• A calorie-reduced diet, regardless of macronutrient composition, provided it achieves a sustained energy deficit

• Mediterranean-style eating patterns, rich in vegetables, legumes, whole grains, fish and unsaturated fats

• Reduced intake of ultra-processed foods, refined carbohydrates and added sugars, which are associated with visceral fat accumulation

• Low-carbohydrate diets, which some studies suggest may be associated with preferential visceral fat reduction in the short term, though long-term adherence varies

Physical activity is equally important. Both aerobic exercise (such as brisk walking, cycling or swimming) and resistance training are associated with reductions in visceral fat, and combining the two appears more effective than either alone. Current NHS and UK Chief Medical Officers' Physical Activity Guidelines recommend at least 150 minutes of moderate-intensity aerobic activity per week for adults, alongside muscle-strengthening activities on two or more days per week.^[11][12]

Sleep quality and stress management also influence visceral fat. Chronic sleep deprivation and elevated cortisol from psychological stress promote central fat deposition through hormonal pathways. Addressing these factors alongside diet and exercise produces better outcomes than focusing on nutrition and activity alone. Behavioural support, including structured programmes and regular follow-up, significantly improves adherence and long-term results.

What treatments and support does the NHS offer for central adiposity?

The NHS offers structured lifestyle programmes, pharmacological treatment including GLP-1 receptor agonists and tirzepatide subject to NICE criteria and local commissioning, and bariatric surgery for those with a BMI of 40 or above or 35 or above with significant comorbidities.

The NHS offers a range of interventions for central adiposity, beginning with structured lifestyle support and extending to pharmacological treatment and bariatric surgery for those who meet specific clinical criteria. The appropriate pathway depends on an individual's BMI, waist circumference, comorbidities and previous attempts at weight management.

Tier 1 and Tier 2 support includes referral to NHS weight management programmes, which provide dietary advice, physical activity guidance and behavioural support. The NHS Digital Weight Management Programme offers online support for adults with a BMI of 30 or above (or 27.5 or above for people from certain ethnic backgrounds) who also have type 2 diabetes or hypertension.

Pharmacological treatment is recommended by NICE for eligible individuals when lifestyle intervention alone has not achieved sufficient weight loss. Medicines with NICE recommendations for weight management in adults include orlistat, which reduces dietary fat absorption; semaglutide injection (Wegovy), a GLP-1 receptor agonist available in doses up to 2.4 mg weekly, with a licensed higher maintenance dose of 7.2 mg weekly also available per the UK SmPC; and liraglutide injection (Saxenda), also a GLP-1 receptor agonist. Tirzepatide (Mounjaro), a dual GIP and GLP-1 receptor agonist delivered via a multi-dose KwikPen, is authorised by the MHRA for both type 2 diabetes and chronic weight management.^[16][17] Orforglipron (Foundayo) is a further MHRA-authorised oral option for weight management; individuals should discuss with their clinician whether it falls within locally commissioned pathways.^[18] These medicines are prescribed within NHS specialist weight management services or, where commissioned by the local Integrated Care Board (ICB), in primary care. Access depends on local ICB commissioning decisions and specialist pathway availability, even where NICE recommends a treatment.

Bolt Pharmacy is a GPhC-registered UK online pharmacy offering online weight-management consultations with prescriber review and pharmacist support. Following clinical assessment, a prescriber may consider appropriate treatment options, including licensed weight-management medicines, where clinically suitable.

Bariatric surgery is available on the NHS for adults with a BMI of 40 or above, or 35 or above with a significant obesity-related condition, when other interventions have not been effective. NICE guidance also indicates that surgery may be considered for adults with a BMI of 30 to 34.9 who have recent-onset type 2 diabetes. Ethnicity-related adjustments to BMI thresholds may also apply. Surgery produces substantial and sustained reductions in visceral fat and is associated with remission of type 2 diabetes in a significant proportion of patients.^[20][21] Referral is made through a GP following assessment against NICE criteria, typically via a Tier 3 specialist weight management service.

Scientific References

1. Visceral fat and metabolic inflammation: the portal theory revisited.
2. Overweight and obesity management (NG246): Identifying and assessing overweight, obesity and central adiposity.
3. Calculate your waist to height ratio.
4. Keep the size of your waist to less than half of your height, NICE recommends.
5. Overweight and obesity management (NG246): Appendix A1 – Summary of evidence from surveillance.
6. The predictive value of a body shape index as a novel obesity metric for cancer risk: a systematic review and meta-analysis.
7. Highlights of mechanisms and treatment of obesity-related hypertension.
8. Obesity, kidney dysfunction, and inflammation: interactions in hypertension.
9. Greater beneficial effects of visceral fat reduction compared with subcutaneous fat reduction on parameters of the metabolic syndrome.
10. Effect of Distinct Lifestyle Interventions on Mobilization of Fat Storage Pools: CENTRAL Magnetic Resonance Imaging Randomized Controlled Trial.
11. Physical activity guidelines for adults aged 19 to 64.
12. UK Chief Medical Officers' physical activity guidelines.
13. Medicines regulator approves up to 7.2 mg dose of semaglutide (Wegovy) for patients with obesity.
14. Wegovy EPAR product information.
15. Semaglutide – BNF NICE.
16. MHRA authorises diabetes drug Mounjaro (tirzepatide) for weight management and weight loss.
17. Tirzepatide: a medicine to manage type 2 diabetes and obesity.
18. UK first in Europe to authorise orforglipron for weight management and type 2 diabetes.
19. Overweight and obesity management (NG246): Medicines and surgery.
20. Prognostic Models for Predicting Remission of Diabetes Following Bariatric Surgery: A Systematic Review and Meta-analysis.
21. Roux-En-Y Gastric Bypass in Type 2 Diabetes Patients with Mild Obesity: a Systematic Review and Meta-analysis.
22. Overweight and obesity in adults.

Frequently Asked Questions